Biological markers for breast carcinoma

T. P. Waalkes, J. P. Enterline, J. H. Shaper, M. D. Abeloff, David S Ettinger

Research output: Contribution to journalArticle

Abstract

During the last decade, there has been an intense search for biological markers for breast carcinoma. Many different types of materials have been found that may be elevated in the body fluids of patients with this disease. However, no markers specific for breast cancer have been discovered and those currently available lack the sensitivity and specificity for early detection of the disease or for determining when the tumor burden is low. Problems may also occur in the interpretation of marker data due to apparent biological variations in synthesis or secretion. Plasma carcinoembryonic antigen (CEA) elevated in 60%-70% of patients with metastases, had had the most extensive evaluation. For the latter patients with increased plasma CEA, the levels in general are proportional to tumor burden. Changes in level with therapy correlate with measurable clinical parameters of response or progression in the majority of these patients. Specific patterns of serial CEA measurements after mastectomy may be helpful for predicting those patients most likely to develop recurrent disease. More recent attention has focused on trials of combination markers and on tissue measurement. The search for a specific marker for breast cancer using monoclonal antibody techniques is a promising area of considerable research interest.

Original languageEnglish (US)
Pages (from-to)644-651
Number of pages8
JournalCancer
Volume53
Issue number3 SUPPL.
StatePublished - 1984

Fingerprint

Biomarkers
Breast Neoplasms
Carcinoembryonic Antigen
Tumor Burden
Mastectomy
Body Fluids
Early Diagnosis
Monoclonal Antibodies
Neoplasm Metastasis
Sensitivity and Specificity
Research
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Waalkes, T. P., Enterline, J. P., Shaper, J. H., Abeloff, M. D., & Ettinger, D. S. (1984). Biological markers for breast carcinoma. Cancer, 53(3 SUPPL.), 644-651.

Biological markers for breast carcinoma. / Waalkes, T. P.; Enterline, J. P.; Shaper, J. H.; Abeloff, M. D.; Ettinger, David S.

In: Cancer, Vol. 53, No. 3 SUPPL., 1984, p. 644-651.

Research output: Contribution to journalArticle

Waalkes, TP, Enterline, JP, Shaper, JH, Abeloff, MD & Ettinger, DS 1984, 'Biological markers for breast carcinoma', Cancer, vol. 53, no. 3 SUPPL., pp. 644-651.
Waalkes TP, Enterline JP, Shaper JH, Abeloff MD, Ettinger DS. Biological markers for breast carcinoma. Cancer. 1984;53(3 SUPPL.):644-651.
Waalkes, T. P. ; Enterline, J. P. ; Shaper, J. H. ; Abeloff, M. D. ; Ettinger, David S. / Biological markers for breast carcinoma. In: Cancer. 1984 ; Vol. 53, No. 3 SUPPL. pp. 644-651.
@article{5e8c65422cf7428e9ed661534e71b73e,
title = "Biological markers for breast carcinoma",
abstract = "During the last decade, there has been an intense search for biological markers for breast carcinoma. Many different types of materials have been found that may be elevated in the body fluids of patients with this disease. However, no markers specific for breast cancer have been discovered and those currently available lack the sensitivity and specificity for early detection of the disease or for determining when the tumor burden is low. Problems may also occur in the interpretation of marker data due to apparent biological variations in synthesis or secretion. Plasma carcinoembryonic antigen (CEA) elevated in 60{\%}-70{\%} of patients with metastases, had had the most extensive evaluation. For the latter patients with increased plasma CEA, the levels in general are proportional to tumor burden. Changes in level with therapy correlate with measurable clinical parameters of response or progression in the majority of these patients. Specific patterns of serial CEA measurements after mastectomy may be helpful for predicting those patients most likely to develop recurrent disease. More recent attention has focused on trials of combination markers and on tissue measurement. The search for a specific marker for breast cancer using monoclonal antibody techniques is a promising area of considerable research interest.",
author = "Waalkes, {T. P.} and Enterline, {J. P.} and Shaper, {J. H.} and Abeloff, {M. D.} and Ettinger, {David S}",
year = "1984",
language = "English (US)",
volume = "53",
pages = "644--651",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "3 SUPPL.",

}

TY - JOUR

T1 - Biological markers for breast carcinoma

AU - Waalkes, T. P.

AU - Enterline, J. P.

AU - Shaper, J. H.

AU - Abeloff, M. D.

AU - Ettinger, David S

PY - 1984

Y1 - 1984

N2 - During the last decade, there has been an intense search for biological markers for breast carcinoma. Many different types of materials have been found that may be elevated in the body fluids of patients with this disease. However, no markers specific for breast cancer have been discovered and those currently available lack the sensitivity and specificity for early detection of the disease or for determining when the tumor burden is low. Problems may also occur in the interpretation of marker data due to apparent biological variations in synthesis or secretion. Plasma carcinoembryonic antigen (CEA) elevated in 60%-70% of patients with metastases, had had the most extensive evaluation. For the latter patients with increased plasma CEA, the levels in general are proportional to tumor burden. Changes in level with therapy correlate with measurable clinical parameters of response or progression in the majority of these patients. Specific patterns of serial CEA measurements after mastectomy may be helpful for predicting those patients most likely to develop recurrent disease. More recent attention has focused on trials of combination markers and on tissue measurement. The search for a specific marker for breast cancer using monoclonal antibody techniques is a promising area of considerable research interest.

AB - During the last decade, there has been an intense search for biological markers for breast carcinoma. Many different types of materials have been found that may be elevated in the body fluids of patients with this disease. However, no markers specific for breast cancer have been discovered and those currently available lack the sensitivity and specificity for early detection of the disease or for determining when the tumor burden is low. Problems may also occur in the interpretation of marker data due to apparent biological variations in synthesis or secretion. Plasma carcinoembryonic antigen (CEA) elevated in 60%-70% of patients with metastases, had had the most extensive evaluation. For the latter patients with increased plasma CEA, the levels in general are proportional to tumor burden. Changes in level with therapy correlate with measurable clinical parameters of response or progression in the majority of these patients. Specific patterns of serial CEA measurements after mastectomy may be helpful for predicting those patients most likely to develop recurrent disease. More recent attention has focused on trials of combination markers and on tissue measurement. The search for a specific marker for breast cancer using monoclonal antibody techniques is a promising area of considerable research interest.

UR - http://www.scopus.com/inward/record.url?scp=0021343032&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021343032&partnerID=8YFLogxK

M3 - Article

C2 - 6692267

AN - SCOPUS:0021343032

VL - 53

SP - 644

EP - 651

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 3 SUPPL.

ER -